Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Unitaid
Deal Size : Undisclosed
Deal Type : Agreement
Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment
Details : Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price for the treatment of tuberculosis.
Product Name : Rifapentine/Isoniazid-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
July 10, 2022
Lead Product(s) : Rifapentine,Isoniazid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Unitaid
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
